{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T07:15:10Z","timestamp":1789542910060,"version":"build-2803163510"},"reference-count":33,"publisher":"BMJ","issue":"4","funder":[{"DOI":"10.13039\/501100012246","name":"Priority Academic Program Development of Jiangsu Higher Education Institutions","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012246","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Science and Technology Development Fund Key Project of Nanjing Medical University"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2018,1,31]]},"published-print":{"date-parts":[[2018,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      The\n                      <jats:italic>human leucocyte antigen-DO<\/jats:italic>\n                      (\n                      <jats:italic>HLA-DO<\/jats:italic>\n                      ) gene located in the\n                      <jats:italic>HLA<\/jats:italic>\n                      non-classical class-II region may play a role in treatment response to hepatitis C virus (HCV). This study was conducted to explore the role of single nucleotide polymorphisms (SNPs) in\n                      <jats:italic>HLA-DO<\/jats:italic>\n                      in responding to HCV therapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>All patients were recruited between January 2011 and September 2016 from the Jurong People\u2019s Hospital, Jiangsu Province, China.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>A total of 346 chronic hepatitis C (CHC) patients who finished the 48-week pegylated interferon-alpha and ribavirin (PEG IFN-\u03b1\/RBV) treatment were enrolled in this study. All patients were former remunerated blood donors. The inclusion criteria for patients were as follows: (1) treatment-naive and treated with PEG IFN-\u03b1\/RBV, (2) HCV RNA was present in serum for over 6 months before treatment, (3) negative for hepatitis B (HBV) or HIV infection and (4) lacked any other hepatic diseases.<\/jats:p>\n                    <jats:p>All participants in this study were Chinese Han population and infected with HCV genotype 1b and treated with subcutaneous PEG IFN-\u03b1 at a dose of 180\u2009\u00b5g once a week with the addition of 800\u20131000\u2009mg\/d RBV according to weight orally for 48 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The SNPs\n                      <jats:italic>HLA-DOA<\/jats:italic>\n                      rs1044429 and\n                      <jats:italic>HLA-DOB<\/jats:italic>\n                      rs2284191 and rs2856997 of 18 SNPs were correlated with HCV treatment response in the Chinese Han population. The dominant model indicated that patients carrying favourable genotypes at rs1044429 AA and rs2284191 AA were more likely to achieve sustained virological response (SVR) (OR 1.99, 95% CI 1.25 to 3.19; OR 2.71, 95%\u2009CI 1.58 to 4.63, respectively), while patients carrying unfavourable genotypes at rs2856997 GG were less likely to achieve SVR (OR 0.48, 95%\u2009CI 0.29 to 0.78).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Genetic variations at rs1044429, rs2284191 and rs2856997 were independent predictors of HCV treatment response in the Chinese Han population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2017-019406","type":"journal-article","created":{"date-parts":[[2018,4,13]],"date-time":"2018-04-13T02:27:04Z","timestamp":1523586424000},"page":"e019406","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Association between\n                    <i>human leucocyte antigen-DO<\/i>\n                    polymorphisms and interferon\/ribavirin treatment response in hepatitis C virus type 1 infection in Chinese population: a prospective study"],"prefix":"10.1136","volume":"8","author":[{"given":"Yinan","family":"Yao","sequence":"first","affiliation":[{"name":"Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Zang","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Yue","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueshan","family":"Xia","sequence":"additional","affiliation":[{"name":"Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Feng","sequence":"additional","affiliation":[{"name":"Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haozhi","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Institute of Epidemiology and Microbiology, Huadong Research Institute for Medicine and Biotechnics, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0146-921X","authenticated-orcid":false,"given":"Peng","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical University, Nanjing, China"},{"name":"Key Laboratory of Infectious Diseases, School of Public Health, Nanjing Medical University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongbin","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical University, Nanjing, China"},{"name":"Key Laboratory of Infectious Diseases, School of Public Health, Nanjing Medical University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,4,12]]},"reference":[{"key":"2025121300264446000_8.4.e019406.1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26141"},{"key":"2025121300264446000_8.4.e019406.2","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2013.107"},{"key":"2025121300264446000_8.4.e019406.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61728-0"},{"key":"2025121300264446000_8.4.e019406.4","doi-asserted-by":"publisher","DOI":"10.1055\/s-2004-832922"},{"key":"2025121300264446000_8.4.e019406.5","doi-asserted-by":"crossref","unstructured":"Pol S , Vallet-Pichard A , Corouge M , et al . Hepatitis C: epidemiology, diagnosis, natural history and therapy. Contrib Nephrol 2012;176.doi:10.1159\/000332374","DOI":"10.1159\/000332374"},{"key":"2025121300264446000_8.4.e019406.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(12)60010-5"},{"key":"2025121300264446000_8.4.e019406.7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2008.01012.x"},{"key":"2025121300264446000_8.4.e019406.8","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1053\/jhep.2003.50350","article-title":"High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C","volume":"38","author":"Bressler","year":"2003","journal-title":"Hepatology"},{"key":"2025121300264446000_8.4.e019406.9","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510260721"},{"key":"2025121300264446000_8.4.e019406.10","doi-asserted-by":"publisher","DOI":"10.1136\/gut.34.2_Suppl.S139"},{"key":"2025121300264446000_8.4.e019406.11","doi-asserted-by":"publisher","DOI":"10.1038\/nri3084"},{"key":"2025121300264446000_8.4.e019406.12","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.09.121"},{"key":"2025121300264446000_8.4.e019406.13","doi-asserted-by":"crossref","first-page":"5395","DOI":"10.3748\/wjg.v19.i33.5395","article-title":"HLA class II associated with outcomes of hepatitis B and C infections","volume":"19","author":"Tamori","year":"2013","journal-title":"World J Gastroenterol"},{"key":"2025121300264446000_8.4.e019406.14","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-14-1"},{"key":"2025121300264446000_8.4.e019406.15","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-4-201302190-00003"},{"key":"2025121300264446000_8.4.e019406.16","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.meegid.2017.07.023","article-title":"The impact of genetic variation in IL28B, IFNL4 and HLA genes on treatment responses against chronic hepatitis C virus infection","volume":"54","author":"Sakhaee","year":"2017","journal-title":"Infect Genet Evol"},{"key":"2025121300264446000_8.4.e019406.17","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00705-016-3095-1","article-title":"IL28B rs12980275 and HLA rs4273729 genotypes as a powerful predictor factor for rapid, early, and sustained virologic response in patients with chronic hepatitis C","volume":"162","author":"Sedighimehr","year":"2017","journal-title":"Arch Virol"},{"key":"2025121300264446000_8.4.e019406.18","doi-asserted-by":"publisher","DOI":"10.1016\/S0952-7915(01)00294-1"},{"key":"2025121300264446000_8.4.e019406.19","doi-asserted-by":"crossref","unstructured":"Benjamini Y , Hochberg Y . Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B 1995:289\u2013300.doi:10.2307\/2346101","DOI":"10.1111\/j.2517-6161.1995.tb02031.x"},{"key":"2025121300264446000_8.4.e019406.20","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.12.056"},{"key":"2025121300264446000_8.4.e019406.21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1872-034X.2010.00671.x"},{"key":"2025121300264446000_8.4.e019406.22","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v11.i46.7302"},{"key":"2025121300264446000_8.4.e019406.23","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/S0140-6736(99)91443-5","article-title":"Influence of MHC class II genotype on outcome of infection with hepatitis C virus","volume":"354","author":"Thursz","year":"1999","journal-title":"The Lancet"},{"key":"2025121300264446000_8.4.e019406.24","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0676.2000.020003234.x"},{"key":"2025121300264446000_8.4.e019406.25","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir726"},{"key":"2025121300264446000_8.4.e019406.26","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.3390\/ijerph13101030","article-title":"Polymorphisms of HLA-DM on Treatment response to interferon\/ribavirin in patients with chronic hepatitis C virus type 1 infection","volume":"13","author":"Chen","year":"2016","journal-title":"Int J Environ Res Public Health"},{"key":"2025121300264446000_8.4.e019406.27","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.3.813"},{"key":"2025121300264446000_8.4.e019406.28","doi-asserted-by":"publisher","DOI":"10.1038\/nri2674"},{"key":"2025121300264446000_8.4.e019406.29","first-page":"1485","article-title":"Polymorphism of HLA-DMA and DMB alleles in patients with systemic lupus erythematosus","volume":"30","author":"Morel","year":"2003","journal-title":"J Rheumatol"},{"key":"2025121300264446000_8.4.e019406.30","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/gene.2014.42","article-title":"SNP screening of central MHC-identified HLA-DMB as a candidate susceptibility gene for HIV-related Kaposi\u2019s sarcoma","volume":"15","author":"Aissani","year":"2014","journal-title":"Genes Immun"},{"key":"2025121300264446000_8.4.e019406.31","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1471-230X-9-5","article-title":"A study of best positive predictors for sustained virologic response to interferon alpha plus ribavirin therapy in naive chronic hepatitis C patients","volume":"9","author":"Idrees","year":"2009","journal-title":"BMC Gastroenterol"},{"key":"2025121300264446000_8.4.e019406.32","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/0140-6736(92)91311-U","article-title":"HCV genotypes in chronic hepatitis C and response to interferon","volume":"339","author":"Kanai","year":"1992","journal-title":"Lancet"},{"key":"2025121300264446000_8.4.e019406.33","doi-asserted-by":"publisher","DOI":"10.1136\/gut.34.12.1714"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2017-019406","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T08:26:57Z","timestamp":1765614417000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2017-019406"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":33,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2018,4,12]]},"published-print":{"date-parts":[[2018,4]]}},"alternative-id":["10.1136\/bmjopen-2017-019406"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2017-019406","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4]]}}}